Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway.
Koetz-Ploch L, Hanniford D, Dolgalev I, Sokolova E, Zhong J, Díaz-Martínez M, Bernstein E, Darvishian F, Flaherty KT, Chapman PB, Tawbi H, Hernando E. Koetz-Ploch L, et al. Among authors: tawbi h. Pigment Cell Melanoma Res. 2017 May;30(3):328-338. doi: 10.1111/pcmr.12578. Epub 2017 Apr 19. Pigment Cell Melanoma Res. 2017. PMID: 28140520 Free PMC article.
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D. Long GV, et al. Among authors: tawbi h. Lancet Oncol. 2012 Nov;13(11):1087-95. doi: 10.1016/S1470-2045(12)70431-X. Epub 2012 Oct 8. Lancet Oncol. 2012. PMID: 23051966 Clinical Trial.
Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.
Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS. Paraiso KH, et al. Among authors: tawbi h. Cancer Discov. 2015 Mar;5(3):264-73. doi: 10.1158/2159-8290.CD-14-0293. Epub 2014 Dec 26. Cancer Discov. 2015. PMID: 25542447 Free PMC article.
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
Hallmeyer S, Gonzalez R, Lawson DH, Cranmer LD, Linette GP, Puzanov I, Taback B, Cowey CL, Ribas A, Daniels GA, Moore T, Gibney GT, Tawbi H, Whitman E, Lee G, Mun Y, Liu S, Hamid O. Hallmeyer S, et al. Among authors: tawbi h. Melanoma Res. 2017 Dec;27(6):585-590. doi: 10.1097/CMR.0000000000000398. Melanoma Res. 2017. PMID: 29076950 Clinical Trial.
Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions.
Glitza IC, Smalley KSM, Brastianos PK, Davies MA, McCutcheon I, Liu JKC, Ahmed KA, Arrington JA, Evernden BR, Smalley I, Eroglu Z, Khushalani N, Margolin K, Kluger H, Atkins MB, Tawbi H, Boire A, Forsyth P. Glitza IC, et al. Among authors: tawbi h. Pigment Cell Melanoma Res. 2020 Jul;33(4):527-541. doi: 10.1111/pcmr.12861. Epub 2020 Jan 19. Pigment Cell Melanoma Res. 2020. PMID: 31916400 Free PMC article. Review.
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.
Yam C, Xu X, Davies MA, Gimotty PA, Morrissette JJD, Tetzlaff MT, Wani KM, Liu S, Deng W, Buckley M, Zhao J, Amaravadi RK, Haas NB, Kudchadkar RR, Pavlick AC, Sosman JA, Tawbi H, Walker L, Schuchter LM, Karakousis GC, Gangadhar TC. Yam C, et al. Among authors: tawbi h. Clin Cancer Res. 2018 Jan 1;24(1):22-32. doi: 10.1158/1078-0432.CCR-17-1807. Epub 2017 Oct 19. Clin Cancer Res. 2018. PMID: 29051322 Free PMC article. Clinical Trial.
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.
Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM. Eroglu Z, et al. Among authors: tawbi h. Pigment Cell Melanoma Res. 2019 May;32(3):458-469. doi: 10.1111/pcmr.12771. Epub 2019 Feb 19. Pigment Cell Melanoma Res. 2019. PMID: 30712316 Free PMC article.
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma.
White MG, Szczepaniak Sloane R, Witt RG, Reuben A, Gaudreau PO, Andrews MC, Feng N, Johnson S, Class CA, Bristow C, Wani K, Hudgens C, Nezi L, Manzo T, De Macedo MP, Hu J, Davis R, Jiang H, Prieto P, Burton E, Hwu P, Tawbi H, Gershenwald J, Lazar AJ, Tetzlaff MT, Overwijk W, Woodman SE, Cooper ZA, Marszalek JR, Davies MA, Heffernan TP, Wargo JA. White MG, et al. Among authors: tawbi h. Oncoimmunology. 2021 Nov 6;10(1):1992880. doi: 10.1080/2162402X.2021.1992880. eCollection 2021. Oncoimmunology. 2021. PMID: 34777916 Free PMC article.
Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions.
Shui IM, Scherrer E, Frederickson A, Li JW, Mynzhassarova A, Druyts E, Tawbi H. Shui IM, et al. Among authors: tawbi h. Melanoma Res. 2022 Dec 1;32(6):393-404. doi: 10.1097/CMR.0000000000000850. Epub 2022 Oct 7. Melanoma Res. 2022. PMID: 36223314
214 results